Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on December 18, 2025, covering the event date of December 12, 2025. The Company is a Delaware corporation with its principal executive offices in Norwood, Massachusetts, and its common stock trades on The Nasdaq Capital Market under the symbol CRBP.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director from the Board of Directors. Alan Holmer has resigned from the Board, effective December 31, 2025, due to retirement. The Company explicitly states that this resignation was not the result of any disagreement with the Company or its management regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks, contingencies, or unusual items are disclosed in this report beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Alan Holmer is resigning from the Board of Directors effective December 31, 2025.
- The resignation is attributed to retirement and is not linked to any internal disagreement.
- The report was signed by Yuval Cohen, Chief Executive Officer, on December 18, 2025.
- No financial data or operational metrics are included in this specific filing.